Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Allogene Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Allogene Therapeutics, Inc.

ALLO

Allogene Therapeutics, Inc.

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company developing genetically engineered allogeneic CAR T cell therapies for cancer and autoimmune diseases. Its off-the-shelf T cell products, derived from healthy donors, target antigens like CD19 and CD70 to treat hematologic malignancies, solid tumors, and autoimmune disorders. The company’s platform emphasizes scalable manufacturing, reduced graft-versus-host disease risk, and faster patient access compared to autologous therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Allogene Therapeutics, Inc.

1
1
Allogene Therapeutics, Inc. Allogene Therapeutics Reports $42.6 Million Net Loss in Q1 2026, Improves from Previous Year

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Allogene Therapeutics, Inc. Allogene Therapeutics Reports $190.9 Million Net Loss for 2025, Decreases in R&D and Administrative Expenses

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Allogene Therapeutics, Inc. Allogene Therapeutics Reports $41.4 Million Net Loss in Q3 2025, Down from $66.3 Million in Q3 2024

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Allogene Therapeutics, Inc. Allogene Therapeutics Reports $50.9 Million Net Loss in Q2 2025, Workforce Reduction and Clinical Advancements Highlighted

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Allogene Therapeutics, Inc. Allogene Therapeutics Reports $59.7 Million Net Loss in Q1 2025, Workforce Reduction Implemented

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Allogene Therapeutics, Inc. Allogene Therapeutics Reports $257.59 Million Net Loss for 2024, Revenue Drops 77%

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Allogene Therapeutics, Inc. Allogene Therapeutics Reports 6% Increase in Net Loss, $403M Cash Reserves in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments